상세 보기
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer
- Jo, H.;
- Lee, M-S;
- Lee, Y-P;
- Kim, H.;
- Hong, J. Y.;
- ... Lee, J.;
- ... Park, S. H.;
- ... Park, J. O.;
- ... Park, Y. S.;
- ... Kim, S. T.;
- 외 2명
WEB OF SCIENCE
4SCOPUS
4초록
Aim: To compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy. Materials and methods: We analysed the treatment outcomes of patients receiving FOLFIRI in combination with bevacizumab or aflibercept as second-line treatment for mCRC between October 2017 and March 2020. This analysis included 67 patients receiving FOLFIRI plus aflibercept and 83 receiving FOLFIRI plus bevacizumab. Results: The overall response rate (ORR) was 13.6% (95% confidence interval 4.85-22.34) in the FOLFIRI-aflibercept group and 14.7% (95% confidence interval 6.68-22.71) in the FOLFIRI-bevacizumab group. This difference in ORR was not statistically significant. The median progression-free survival was 8.6 months in the FOLFIRI-bevacizumab group and 8.5 months in the FOLFIRI-aflibercept group (P = 0.752). Patients in the FOLFIRI-bevacizumab group showed a median overall survival of 12.4 months, whereas patients in the FOLFIRI-aflibercept group had a median overall survival of 13.7 months (P = 0.276). There were no significant differences in survival between the two treatment groups. The adverse events were also largely similar between the two groups. However, hy-pertension of grade 3 or more was more frequent in the FOLFIRI-aflibercept group. Conclusion: FOLFIRI plus bevacizumab and FOLFIRI plus aflibercept had similar anti-tumour activities and toxicity profiles when used as second-line therapy in mCRC patients. Based on these data, both aflibercept and bevacizumab are suitable anti-angiogenic agents when used in combination with FOLFIRI for mCRC. (C) 2022 The Author(s). Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
키워드
- 제목
- A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer
- 저자
- Jo, H.; Lee, M-S; Lee, Y-P; Kim, H.; Hong, J. Y.; Lee, J.; Park, S. H.; Park, J. O.; Park, Y. S.; Lim, H. Y.; Kang, W. K.; Kim, S. T.
- 발행일
- 2022-08
- 유형
- Article
- 권
- 34
- 호
- 8
- 페이지
- E323 ~ E328
- 언어
- ENG
- 출판사
- W. B. Saunders Co., Ltd.
- 발행국가
- 영국
- ISSN
- E 1433-2981
P 0936-6555